분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-11-13 13:51:18 , Hit : 2692
 Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-

A genetically engineered smallpox vaccine improved the survival of liver cancer patients participating in a Phase II clinical trial.

By Cristina Luiggi | November 11, 2011

High doses of a smallpox vaccine modified to lyse cancer cells improved the survival rates of patients with advanced liver cancer, according to the results of Phase II clinical trials, which were reported last weekend at the American Association for the Study of Liver Diseases meeting.

Developed by the San Francisco-based biotech, Jennerex, the JX-594 vaccine uses the pox strain once used to vaccinate people against smallpox, but which has been genetically altered to specifically infect solid tumors by targeting common genetic cancer defects. When administered at varying doses to 30 liver cancer patients participating in a mid-stage clinical trial run jointly by Jennerex and the University of California, San Diego, patients who received high doses lived for a median of 13.8 months, whereas patients who received one tenth of the dose lived just 6-7 months. In light of the promising results, Jennerex plans to launch a Phase III trials in 2012 comparing the JX-594 vaccine with Nexavar, a kinase inhibitor currently used to treat advanced kidney and liver patients,

By Deena Beasley

Sat Nov 5, 2011 9:03am EDT

------------------------------------------------------------------------------

(Reuters) - A genetically engineered smallpox vaccine reduced the risk of death for patients with advanced liver cancer by nearly 60 percent in a mid-stage study, prompting the launch of a later-stage trial.

Scientists at institutions including the University of California, San Diego, and privately held biotech company Jennerex Inc presented Phase 2 trial data on Saturday showing that patients given high doses of the altered vaccine, known as JX-594, lived for a median of 13.8 months compared with 6.7 months for patients treated with one-tenth of that dose.

The small 30-patient study found that 66 percent of the high-dose patients were alive after one year, compared with 23 percent of the low-dose group.

Temporary flu-like symptoms were the main side effect seen in the trial, which was presented in San Francisco at a meeting of the American Association for the Study of Liver Diseases.

Scientists have been intrigued for decades with the idea of using viruses to alert the immune system to seek and destroy cancerous cells. That interest has taken off in recent years as advances in genetic engineering allow them to customize viruses that target tumors.

JX-594 is derived from a strain of the virus vaccinia, once commonly used to vaccinate children against smallpox.

"Viruses are inherently cancer selective and tumor cells are inherently susceptible to viral attack," said Dr. David Kirn, chief medical officer at Jennerex. "We enhance selectivity by further attenuating and weakening the virus in normal tissue."

He said the first patient has been enrolled in a Phase 2b study comparing JX-594 with standard care in 120 liver cancer patients who have stopped responding to Nexavar, also known as sorafenib, sold by Onyx Pharmaceuticals.

Patients in the trial will first be given an intravenous infusion of JX-594, followed by direct injections into the tumor. Dr. Kirn said the trial will also allow for more continuous dosing than in earlier studies.

Jennerex plans to launch next year a Phase 3 head-to-head trial comparing JX-594 with Nexavar and is conducting earlier-stage trials in other types of cancer.

Other forays into using engineered viruses include biotech giant Amgen Inc's deal in January to pay up to $1 billion for BioVex and its cancer drug development platform based on the herpes simplex virus.

Amgen said last month that it had completed enrollment in a Phase 3 trial of the therapy in melanoma patients.

Jennerex is primarily funded by investors from Canada and South Korea. European rights to JX-594 have been licensed to Transgene SA. Other regional licenses are held by Lee's Pharmaceutical Ltd for China and Green Cross Corp for South Korea.

(Reporting by Deena Beasley; Editing by Steve Orlofsky)








827   Vertex study will evaluate 12-week treatment period for some hepatitis C patients  이성욱 2011/10/25 2889
826   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3645
825   Going Viral  이성욱 2011/10/28 2663
824   GlaxoSmithKline is first partner for new Alnylam platform  이성욱 2011/11/02 2580
823   Do Bacteria Age? Biologists Discover the Answer Follows Simple Economics  이성욱 2011/11/04 2440
822   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2403
821   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2487
820   How Blood Cells Thwart Malaria  이성욱 2011/11/13 3419
  Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-  이성욱 2011/11/13 2692
818   AASLD: African-Americans Face Hep C 'Triple Whammy'  이성욱 2011/11/17 2410
817   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2612
816   Finger (mal)formation reveals surprise function of desert DNA  이성욱 2011/11/28 2768
815   Stem-cell pioneer bows out  이성욱 2011/11/28 2487
814   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2665
813   Treatment for Blood Disease Is Gene Therapy Landmark  이성욱 2011/12/13 2032
812   Vertex begins joint studies on hepatitis C compounds  이성욱 2011/12/13 2671
811   Former Reginans changing the future of HIV  이성욱 2011/12/28 2311
810   The RNA roots of obesity?  이성욱 2012/01/03 2293
809   Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans  이성욱 2012/01/22 2488
808   Can DNA Self-replicate?  이성욱 2012/01/22 2493

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN